English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

ShangPharma Obtains China Rights to Mabspace Antibody Technology

Nov. 27, 2013

ShangPharma, one of China’s largest CROs, signed an exclusive China license agreement with Mabspace International for specific Mabspace antigens and technology for CRO use in antibody discovery. Founded in 2011, Mabspace develops novel, fast follow-on antibody-based therapeutic agents that target chronic kidney diseases, cancer and autoimmune disorders. Mabspace is headquartered in Hong Kong with a mainland subsidiary in Suzhou BioBay.